Sisplatin ve Karboplatin Yüklü Albumin Nanopartiküllerin Meme Kanseri Hücreleri Üzerindeki Sitotoksik Etkileri

Abstract

Amaç: Bu çalışmanın amacı kanser tedavisinde sıklıkla kullanılan karboplatin ve sisplatin ilaçlarının albümin nanotaşıyıcıya yüklenerek antikanser etkilerinin araştırılması ve karşılaştırılmasıdır. Materyal ve Metot: Karboplatin (CP) ve Sisplatin (Cis) yüklenmiş albümin nanopartiküller, sırasıyla CP-NPs ve Cis-NPs olarak ultrasonikasyon kullanarak sentezlendi. Nanopartikül boyutu ve dağılımın homojenitesi Dinamik ışık saçılımı (DLS) ile değerlendirildi. Nanopartiküllerin sitotoksik aktiviteleri MDA-MB-231 ve MCF-7 meme kanseri hücrelerinde ve HUVEC hücrelerinde, MTT testi kullanılarak değerlendirildi ve morfolojik görüntüleri karşılaştırıldı. Bulgular: CP-NPs’lerin boyutu ortalama 2-3 nm civarında iken, Cis-NPs’lerin 7-8 nm idi. Her iki nanopartikül grubunun da homojen bir şekilde dağıldığı görüldü. Sitotoksisite sonuçlarına göre CP-NPs ve Cis-NPs, MCF-7 meme kanseri hücrelerinde daha sitotoksikti. Ayrıca CP-NPs ve Cis-NPs’ler MDA-MB-231 meme kanseri hücrelerinde önemli sitotoksisite gösterirken, normal HUVEC hücrelerinde düşük sitotoksisite tespit edildi. CP-NPs ve Cis-NPs ile tedavi edilen MCF-7, tedavi edilmeyen MCF-7 ile karşılaştırıldı ve NPs'ler için istatistiksel anlamlılık P<0,01 olarak hesaplandı. Sonuç: Meme kanseri hücrelerinde yüksek sitotoksisite gözlenirken, sağlıklı hücrelerde belirgin sitotoksisite gözlenmemiş olup albümine bağlı CP-NPs ve Cis-NPs kanser tedavisinde umut vadedici bir tedavi seçeneği olabilir.

Keywords

• MCF-7
• MDA-MB-231
• meme kanseri
• nano ilaç
• sitotoksisite

Cytotoxic Effects of Cisplatin and Carboplatin Loaded Albumin Nanoparticles on Breast Cancer Cells

Abstract

Objective: This study aims to investigate and compare the anticancer effects of carboplatin and cisplatin, frequently used in cancer treatment, by loading them on albumin nanocarrier. Materials and Methods: Carboplatin (CP) and Cisplatin (Cis) loaded albumin nanoparticles were synthesized using ultrasonication as CP-NPs and Cis-NPs, respectively. Nanoparticle size and distribution were evaluated by Dynamic light scattering (DLS). Cytotoxicities of NPs were evaluated in MDA-MB-231 and MCF-7 breast cancer cells and HUVEC using MTT test and their morphological images were compared. Results: While the average size of CP-NPs was around 2-3 nm, Cis-NPs was 7-8 nm. It was observed that both NPs groups were homogeneously dispersed. According to the cytotoxicity results, both CP-NPs and Cis-NPs were more cytotoxic on MCF-7 breast cancer cells. In addition, CP-NPs and Cis-NPs showed significant cytotoxicity on MCF-7, MDA-MB-231 breast cancer cells, while low cytotoxicity was detected in normal HUVEC cells. The NPs treated MCF-7 was compared with the untreated MCF-7 and statistical significance was calculated as P<0.01 for CP-NPs and Cis-NPs. Conclusions: Abumin-based CP-NPs and Cis-NPs showed high cytotoxicity in breast cancer cells, they have low cytotoxicity in healthy cells, making them promising for breast cancer treatment.

Keywords

• Cytotoxicity
• breast cancer
• MCF-7
• MDA-MB-231
• nano drug

References

1. 1. Howell A, Anderson AS, Clarke RB, et al. Risk determination and prevention of breast cancer. Breast Cancer Research 2014;16(5):1-19. doi:10.1186/S13058-014-0446-2
2. 2. Reang J, Sharma PC, Kumar Thakur V, et al. Understanding the therapeutic potential of ascorbic acid in the battle to overcome cancer. Biomolecules 2021;11(8):1130. doi:10.3390/BIOM11081130
3. 3. Schirrmacher V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment. Int J Oncol. 2019;54(2):407-419. https://doi.org/10.3892/ijo.2018.4661
4. 4. Zhao CY, Cheng R, Yang Z, Tian ZM. Nanotechnology for cancer therapy based on chemotherapy. Molecules. 2018;23(4). doi:10.3390/molecules23040826
5. 5. Parvanian S, Mostafavi SM, Aghashiri M. Multifunctional nanoparticle developments in cancer diagnosis and treatment. Sens Biosensing Res. 2017;13:81-87. doi:10.1016/J.SBSR.2016.08.002
6. 6. Wu J. The enhanced permeability and retention (epr) effect:The significance of the concept and methods to enhance its application. Journal of Personalized Medicine 2021;11(8):771. doi:10.3390/JPM11080771
7. 7. Ma P, Mumper RJ. Paclitaxel nano-delivery systems: a comprehensive review. J Nanomed Nanotechnol. 2013;4(2):1000164. doi:10.4172/2157-7439.1000164
8. 8. Karami E, Behdani M, Kazemi-Lomedasht F. Albumin nanoparticles as nanocarriers for drug delivery: Focusing on antibody and nanobody delivery and albumin-based drugs. J Drug Deliv Sci Technol. 2020;55:101471. doi:10.1016/J.JDDST.2019.101471

9. 9. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. Journal of Controlled Release. 2012;157(2):168-182. doi:10.1016/J.JCONREL.2011.07.031
10. 10. Lee ES, Youn YS. Albumin-based potential drugs: focus on half-life extension and nanoparticle preparation. Journal of Pharmaceutical Investigation 2016;46(4):305-315. doi:10.1007/S40005-016-0250-3
11. 11. Vaz J, Ansari D, Sasor A, Andersson R. SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer. Pancreas. 2015;44(7):1024. doi:10.1097/MPA.0000000000000409
12. 12. Kratz F. A clinical update of using albumin as a drug vehicle-A commentary. Journal of Controlled Release. 2014;190:331-336. doi:10.1016/J.JCONREL.2014.03.013
13. 13. Hassanin I, Elzoghby A. Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance. Cancer Drug Resistance. 2020;3(4):930-946. doi:10.20517/CDR.2020.68
14. 14. Kalındemirtaş FD, Kariper İA, Sert E, Okşak N, Kuruca SE. The evaluation of anticancer activity by synthesizing 5FU loaded albumin nanoparticles by exposure to UV light. Toxicology in Vitro 2022;84:105435. doi.org/10.1016/j.tiv.2022.105435
15. 15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55-63. doi:10.1016/0022-1759(83)90303-4
16. 16. Dang Y, Guan J. Nanoparticle-based drug delivery systems for cancer therapy. Smart Mater Med. 2020;1:10-19. doi:10.1016/J.SMAIM.2020.04.001
17. 17. Liu Y, Guo Q, Sun H, Guo N, Zhang J. Improved therapeutic efficiency of photothermal treatment and nursing care in prostate cancer by DOX loaded PEG coated Cu@Se nano-hybrid vesicle. Process Biochemistry. 2020;92:78-84. doi:10.1016/J.PROCBIO.2020.02.022
18. 18. Ye BL, Zheng R, Ruan XJ, Zheng ZH, Cai HJ. Chitosan-coated doxorubicin nano-particles drug delivery system inhibits cell growth of liver cancer via p53/PRC1 pathway. Biochem Biophys Res Commun. 2018;495(1):414-420. doi:10.1016/J.BBRC.2017.10.156
19. 19. Haggag YA, Osman MA, El-Gizawy SA, et al. Polymeric nano-encapsulation of 5-fluorouracil enhances anti-cancer activity and ameliorates side effects in solid Ehrlich Carcinoma-bearing mice. Biomedicine & Pharmacotherapy. 2018;105:215-224. doi:10.1016/J.BIOPHA.2018.05.124
20. 20. Vijayakumar S, Ganesan S. Size-dependent in vitro cytotoxicity assay of gold nanoparticles. Toxicological & Environmental Chemistry 2013;95(2):277-287. doi:10.1080/02772248.2013.770858
21. 21. Kocak C, Kocak FE, Ozturk B, Tekin G, Vatansev H. Cytotoxic, anti-proliferative and apoptotic effects of noscapine on human estrogen receptor positive (MCF-7) and negative (MDA-MB-231) breast cancer cell lines. Bratisl Lek Listy. 2020;121(1):43-50. doi:10.4149/BLL_2020_007
22. 22. Noh JI, Mun SK, Lim EH, et al. Induction of apoptosis in MDA-MB-231 cells treated with the methanol extract of lichen physconia hokkaidensis. Journal of Fungi 2021;7(3):188. doi:10.3390/JOF7030188
23. 23. Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020;25(9). doi:10.3390/MOLECULES25092193
24. 24. Zinger A, Koren L, Adir O, et al. Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors. ACS Nano. 2019;13(10):11008-11021 doi: 10.1021/acsnano.9b02395
25. 25. Yan L, Shen J, Wang J, Yang X, Dong S, Lu S. Nanoparticle-based drug delivery system: a patient-friendly chemotherapy for oncology. Dose-Response. 2020;18(3). doi:10.1177/1559325820936161
26. 26. Edis Z, Wang J, Waqas MK, Ijaz M, Ijaz M. Nanocarriers-mediated drug delivery systems for anticancer agents: an overview and Perspectives. Int J Nanomedicine. 2021;16:1313-1330. doi:10.2147/IJN.S289443